Stifel raised the firm’s price target on Intuitive Surgical (ISRG) to $610 from $525 and keeps a Buy rating on the shares. After having had in-depth conversations with five early-adopting U.S. da Vinci 5 robotic system physicians now roughly eight months post FDA approval, the firm says early physician DV5 feedback was “highly-encouraging,” adding that these physicians’ robotic surgery adoption appears “all-in.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical assumed at Overweight from Equal Weight at Morgan Stanley
- Intuitive Surgical price target raised to $561 from $535 at BTIG
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Workday initiated, Kraft Heinz downgraded: Wall Street’s top analyst calls
- Intuitive Surgical upgraded to Buy at Erste on ‘excellent market position’